denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Hodgkin lymphoma, Biological therapies, Antibody Therapy, artificial intelligence (AI), epidemiology, Clinical Practice (Health Services and Quality), Lymphomas, Bispecific Antibody Therapy, Non-Biological therapies, elderly, Clinical Research, health outcomes research, Chemotherapy, Combination therapy, bioinformatics, health disparities research, Diversity, Equity, and Inclusion (DEI) , Checkpoint Inhibitor, patient-reported outcomes, Diseases, real-world evidence, Therapies, Immunotherapy, therapy sequence, registries, Lymphoid Malignancies, Adverse Events, survivorship, Technology and Procedures, Study Population, Human, machine learning, Pathology
Session: How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Hodgkin lymphoma, Biological therapies, Antibody Therapy, artificial intelligence (AI), epidemiology, Clinical Practice (Health Services and Quality), Lymphomas, Bispecific Antibody Therapy, Non-Biological therapies, elderly, Clinical Research, health outcomes research, Chemotherapy, Combination therapy, bioinformatics, health disparities research, Diversity, Equity, and Inclusion (DEI) , Checkpoint Inhibitor, patient-reported outcomes, Diseases, real-world evidence, Therapies, Immunotherapy, therapy sequence, registries, Lymphoid Malignancies, Adverse Events, survivorship, Technology and Procedures, Study Population, Human, machine learning, Pathology
Saturday, December 9, 2023, 4:00 PM-5:15 PM
Disclosures: Evens: Takeda: Consultancy, Honoraria; Morphosys: Consultancy, Honoraria; Epizyme: Consultancy, Honoraria; Pharmacyclics: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria.
OffLabel Disclosure: Checkpoint inhibitors in frontline HL
See more of: How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?
See more of: Education Program
See more of: Education Program
Previous Presentation
|
Next Presentation >>